[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587659":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":7,"responsibleParty":23,"collaborators":25,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":7,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":7,"targetDuration":7,"studyType":39,"phases":7,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":45,"whyStopped":7,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":50,"locationsCount":7},{"fullName":5,"class":6},"Saol Therapeutics Inc","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Dichloroacetate (DCA)","Study medication DCA is an oral solution mixed with an artificial sweetener containing aspartame and strawberry extract (50mg\u002FmL) Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens: EGT carriers will receive 12 mg\u002Fkg\u002F12hr DCA. EGT non-carriers will receive 6 mg\u002Fkg\u002F12 hr DCA.",[14],{"name":15,"affiliation":5,"role":16},"Kiki Diorgu, M.D.","STUDY_CHAIR",[18],{"name":19,"role":20,"phone":21,"phoneExt":7,"email":22},"Kyle Ashton, Ph.D.","CONTACT","770-274-2500","eap@saolrx.com",{"type":24,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[26],{"name":27,"class":28},"AnovoRx","UNKNOWN","100587659","expanded-access-treatment-protocol-with-dca-for-patients-with-pdcd-100587659",false,"NCT06931262","Expanded Access Treatment Protocol With DCA for Patients With PDCD","Expanded Access Treatment Protocol With Dichloroacetate Sodium for Patients With Pyruvate Dehydrogenase Complex Deficiency","Inclusion Criteria:\n\n1. Ages 0 through adulthood\n2. Presence of characteristic clinical or metabolic features of PDCD and\n3. Presence of a known pathogenic mutation of a gene that is specifically associated with PDC (PDHA1, PDHB, DLAT, PDHX, DLD).\n4. Females of reproductive age must be willing to use an effective method of barrier contraception for the duration of the study.-\n\nExclusion Criteria:\n\n1. A genetic mitochondrial disease other than those stipulated under inclusion criteria\n2. Primary, defined organic acidurias other than lactic acidosis (e.g., propionic aciduria)\n3. Primary disorders of amino acid metabolism\n4. Primary disorders of fatty acid oxidation\n5. Secondary lactic acidosis due to impaired oxygenation or circulation (e.g., due to severe cardiomyopathy or congenital heart defects)\n6. Malabsorption syndromes associated with D-lactic acidosis\n7. Renal insufficiency, defined as 1) a requirement for chronic dialysis or 2) serum creatinine ≥ 1.2 mg\u002Fdl or creatinine clearance \\\u003C60 ml\u002Fmin\n8. Primary hepatic disease unrelated to PDCD\n9. Pregnancy or breast feeding -","ALL","0 Years","17 Years","EXPANDED_ACCESS","Expanded Access (EA) will provide a transition to continue therapy for those patients who are currently in the open label extension of the Phase III study, SL 1009-01, while also allowing new patients diagnosed with PDCD who meet the eligibility criteria to also have access to therapy that would be otherwise unavailable.",[42],"Pyruvate Dehydrogenase Complex Deficiency",[44],"PDCD","AVAILABLE","2025-05-05",{"date":48,"type":49},"2025-05-08","ACTUAL",{"name":5,"class":6}]